Seladelpar

Unassigned

New Medicines

Primary biliary cholangitis (PBC) - second or subsequent-line

Information

New molecular entity
CymaBay Therapeutics
CymaBay Therapeutics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

An orally active, potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist
The prevalence of PBC has been estimated as 12.9 per 100,000 population in the UK with up to 90% of cases occurring in women. PBC is more common amongst those of northern European descent and less common amongst those of African origin. Diagnosis is usually between about 45 and 55 years old [1].
Primary biliary cholangitis (PBC) - second or subsequent-line
Oral